Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
|Videos|April 11, 2011
Dr. Dreicer on New Target Agents Improving Treatment
Author(s)Robert Dreicer, MD
Advertisement
Robert Dreicer, MD from the Taussig Cancer Institute on How New Target Agents Can Improve Treatment
Advertisement
Related to this article
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
The FDA granted fast track designation to the PSMA-targeted T-cell engager VIR-5500 for late-line metastatic castration-resistant prostate cancer.
Carotuximab plus apalutamide demonstrated longer median progression-free survival than apalutamide alone in an interim phase 2 analysis in mCRPC.
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
QTX3034 Plus Cetuximab Receives FDA Fast Track Designation in KRAS G12D–Mutated CRC
5